ptpn2-in-1

PTPN2 1-IN-2 is an antagonist of PTPN2 1 utilized in various tumor research studies [1].

Osunprotafib (ABBV-CLS-484) is a potent, orally bioavailable PTP1B PTPN2 inhibitor in clinical trials for solid tumors. [1] Osunprotafib (ABBV-CLS-484) stimulates the tumor microenvironment and promotes natural killer cell and CD8 T cell function and enhances T cell anti-tumor immunity by enhancing JAK-STAT signaling and reducing T cell dysfunction. [2]

PTPN2 ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTAC) utilized in the synthesis of PVD-06.

PROTAC PTPN2 Degrader-1 (compound example 77) is a potent entity capable of degrading PTPN2, showing promise for research applications in cancer or metabolic diseases [1].

Tegeprotafib (PTPN2 1-IN-1) is an orally active and potent PTPN1 2 inhibitor with potential anticancer and antitumor activity for the study of cancer and immune system diseases.

PROTAC PTPN2 degrader-2 (example 187B) is a potent PTPN2-degrading agent with potential applications in cancer and metabolic disease research [1].

PROTAC PTPN2 degrader-2 (example 187B) TFA is a potent Protein Tyrosine Phosphatase Non-receptor Type 2 (PTPN2) degrader with potential applications in cancer and metabolic disease research [1].

Anticancer Agent 143 (Compound 369), a potent dual inhibitor targeting PTPN2 and PTP1B, exhibits IC50 values below 2.5 nM. It is employed in cancer research [1].